13 Biotechnology Stocks to Buy Now

STML, PCYC, ACOR, NWBO, MNOV, ADMA, LJPC, BMRN, SGEN, AMBI, PTLA, ENTA, AMGN improve in weekly rankings

This week, 13 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Stemline Therapeutics, Inc. (STML) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. For more information, get Portfolio Grader’s complete analysis of STML stock.

Pharmacyclics, Inc. (PCYC) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

The rating of Acorda Therapeutics, Inc. (ACOR) moves up this week, rising from a C to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

Northwest Biotherapeutics, Inc. (NWBO) earns a B this week, jumping up from last week’s grade of C. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.

MediciNova, Inc. (MNOV) gets a higher grade this week, advancing from a B last week to an A. Medicinova acquires, develops, and commercializes small molecule therapeutics. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

This is a strong week for ADMA Biologics, Inc. (ADMA). The company’s rating climbs to A from the previous week’s B. Shares of the stock have been trading at an exceptionally rapid pace, up 512.9% from the week prior. For more information, get Portfolio Grader’s complete analysis of ADMA stock.

La Jolla Pharmaceutical Company (LJPC) is seeing ratings go up from a B last week to an A this week. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

BioMarin Pharmaceutical’s (BMRN) ratings are looking better this week, moving up to a B from last week’s C. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

This week, Seattle Genetics, Inc.’s (SGEN) ratings are up from a C last week to a B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Ambit Biosciences Corp. (AMBI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Portola Pharmaceuticals, Inc. (PTLA) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of PTLA stock.

Enanta Pharmaceuticals, Inc. (ENTA) gets a higher grade this week, advancing from a B last week to an A. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of ENTA stock.

This is a strong week for Amgen (AMGN). The company’s rating climbs to A from the previous week’s B. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. The stock has a dividend yield of 3.2%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2014/12/13-biotechnology-stocks-to-buy-now-stml-pcyc-acor/.

©2019 InvestorPlace Media, LLC